Compare LMAT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | STOK |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2006 | 2019 |
| Metric | LMAT | STOK |
|---|---|---|
| Price | $94.30 | $31.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $105.80 | $39.20 |
| AVG Volume (30 Days) | 292.9K | ★ 609.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | 30.57 | ★ 92.73 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $249,602,000.00 | $184,420,000.00 |
| Revenue This Year | $14.21 | N/A |
| Revenue Next Year | $8.88 | $77.49 |
| P/E Ratio | $138.13 | ★ N/A |
| Revenue Growth | 13.53 | ★ 404.50 |
| 52 Week Low | $79.01 | $11.19 |
| 52 Week High | $118.01 | $40.22 |
| Indicator | LMAT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 55.20 |
| Support Level | $82.26 | $30.34 |
| Resistance Level | $97.83 | $35.11 |
| Average True Range (ATR) | 3.02 | 1.54 |
| MACD | 0.63 | 0.28 |
| Stochastic Oscillator | 61.26 | 73.88 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.